Solbinsiran, a durable GalNAc-conjugated siRNA targeting ANGPTL3 in adults with mixed dyslipidaemia (PROLONG-ANG3): lessons from a randomized, placebo-controlled, phase 2 trial
Cardiovascular Research · 22.05.2026 · 122 (7) · 797-800
DOI: 10.1093/cvr/cvag045 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cardiovascular Research, online erschienen am 25.03.2026. Verfasst von Dídac Llop und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Primary Care and Public Health, Imperial Centre for Cardiovascular Disease Prevention, School of Public Health, Imperial College London…. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Primary Care and Public Health, Imperial Centre for Cardiovascular Disease Prevention, School of Public Health, Imperial College London, White City Campus, 90 WoodLane, London W12 0BZ, UK.
Zitieren
APA
Llop, D., & Ray, K. K. (2026). Solbinsiran, a durable GalNAc-conjugated siRNA targeting ANGPTL3 in adults with mixed dyslipidaemia (PROLONG-ANG3): lessons from a randomized, placebo-controlled, phase 2 trial. Cardiovascular Research, 122(7), 797-800. https://doi.org/10.1093/cvr/cvag045
Vancouver
Llop D, Ray KK. Solbinsiran, a durable GalNAc-conjugated siRNA targeting ANGPTL3 in adults with mixed dyslipidaemia (PROLONG-ANG3): lessons from a randomized, placebo-controlled, phase 2 trial. Cardiovascular Research. 2026;122(7):797-800. doi:10.1093/cvr/cvag045
BibTeX
@article{Llop2026,
author = {Llop, Dídac and Ray, Kausik K},
title = {Solbinsiran, a durable GalNAc-conjugated siRNA targeting ANGPTL3 in adults with mixed dyslipidaemia (PROLONG-ANG3): lessons from a randomized, placebo-controlled, phase 2 trial},
journal = {Cardiovascular Research},
year = {2026},
volume = {122},
number = {7},
pages = {797--800},
doi = {10.1093/cvr/cvag045}
}
EUVIMED